SecBot SecBot
PRESS-RELEASE ·Filed Mar 18, 2026

PROK

ProKidney
MIXED
Impact 6/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor enrollment completion in mid-2026 and eGFR slope data in Q2 2027 as key catalysts. While reduced losses and strong cash position de-risk near-term execution, absence of revenue and continued net losses limit bullishness. Positive clinical momentum supports long-term upside, but stock remains binary on Phase 3 outcomes.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.95
T+0 close · Mar 18, 2026 · via day close
Latest settled
−14.36%
T+60 · $1.67
Vs SPY
−28.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 19 $1.95entry
  2. T+1 · 8mo ago −1.03%α +0.72% · $1.93
  3. T+5 · 8mo ago −9.23%α −7.02% · $1.77
  4. T+20 · 7mo ago +11.79%α +4.17% · $2.18
  5. T+60 · 5mo ago −14.36%α −28.70% · $1.67
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProKidney reported financial results for 2025, highlighting a reduction in net loss to $151.6 million from $163.3 million in 2024, driven by lower R&D and G&A expenses. The company maintains a strong clinical trajectory with FDA alignment on an accelerated approval pathway for rilparencel based on eGFR slope, and completed enrollment in its Phase 3 PROACT 1 trial is expected by mid-2026, with pivotal data readout anticipated in Q2 2027. Cash reserves totaled $270.0 million at year-end, sufficient to fund operations into mid-2027.

Key Financial Metrics

Revenue
$893.0K
+1067.1% YoY
EPS
$-1.52

Key Facts

  • Net loss before noncontrolling interest decreased to $151.6 million in 2025 from $163.3 million in 2024.
  • R&D expenses declined to $114.1 million (from $127.7M) due to completion of prior trials, partially offset by increased costs in the ongoing PROACT 1 study.
  • G&A expenses fell to $51.8 million (from $56.1M), driven by lower impairment and equity compensation charges.
  • Cash, cash equivalents, and marketable securities totaled $270.0 million as of December 31, 2025, down from $358.3 million in 2024.
  • Company reaffirmed cash runway into mid-2027, aligning with Phase 3 trial milestones.
  • FDA confirmed eGFR slope as a valid surrogate endpoint for accelerated approval of rilparencel in a July 2025 Type B meeting.
  • Phase 3 PROACT 1 enrollment on track for completion in mid-2026, with topline data expected Q2 2027.

Financial Impact

Reduced annual cash burn by ~$11.7 million year-over-year; ending cash balance of $270.0 million supports operations into mid-2027.

cash runwayR&D expenseG&A expensenet loss

Risk Factors

  • Clinical trial results may not meet expectations, particularly the eGFR slope endpoint in 2027.
  • Regulatory risk: FDA may require additional data beyond the accelerated pathway despite current alignment.
  • Cash runway estimate assumes no delays or cost overruns; any setback could necessitate earlier dilutive financing.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3258574

Track record

13 reports on PROK

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  3. Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
  4. Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
  5. Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  6. Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
  7. Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
  8. Aug 10, 202614w ago 8-K Neutral 5/10 No price data
  9. Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
  10. May 15, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 18, 2026